Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2009

Bonanni Bernardo, Serrano Davide, Gandini Sara, Guerrieri-Gonzaga Aliana, Johansson Harriet, Macis Debora, Cazzaniga Massimiliano, Luini Alberto, Cassano Enrico, Oldani Sabina, Lien Ernst A, Pelosi Giuseppe, Decensi Andrea

Abstract excerpt

PURPOSE: In the Anastrozole, Tamoxifen Alone or in Combination trial, the combination arm was inferior to anastrozole alone in terms of disease-free survival possibly due to an adverse pharmacokinetic interaction or a predominant estrogenic effect of tamoxifen under estrogen deprivation. We assessed whether the addition of a lower dose of tamoxifen influenced anastrozole bioavailability and favorably modulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Disease-Free Survival

Share to Nitriles

Share to Precancerous Conditions

Share to Tamoxifen

Share to Triazoles

Source

Identifiers

PMID: 19887477
DOI: 10.1158/1078-0432.CCR-09-1354

Genes

SHBG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.PMID 19887477Read ↗

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.Semantic proximity Read ↗

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Semantic proximity Read ↗

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical TrialsSemantic proximity Read ↗

Reducing the risk of breast cancer with tamoxifen in women at increased risk.Semantic proximity Read ↗

Anastrozole.Semantic proximity Read ↗

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.Semantic proximity Read ↗

Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.Semantic proximity Read ↗

Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.Semantic proximity Read ↗

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.Semantic proximity Read ↗

Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.Semantic proximity Read ↗

Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.